A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Conditions

• Psoriasis

Eligibility Criteria

Sex

ALL

Age

12 Years - 18 Years

Healthy Volunteers

Not accepted

Interventions

• IBI112 — DRUG
  IBI112 by subcutaneous injection
• placebo — DRUG
  placebo by subcutaneous injection

Study Details

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.

Key Dates

First listed

Dec 4, 2025

Start date

Dec 3, 2025

Status verified

Dec 2025

Primary completion

Sep 30, 2026

Completion

Jan 31, 2029

Study Design

Enrollment

104 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Placebo Comparator: placebo
  Participants receive placebo through week 16,placebo participants will cross over to receive IBI112 through week 44
• Experimental: IBI112
  Participants receive IBI112 through week 44

Primary Outcome Measure

Percentage of patients achieving Psoriasis Area and severity index(PASI) 75 at week 16 [ Time Frame: week 16 ]

Central Contacts

• Bingjing Feng
  +86 18361923769
  [email protected]

Find similar trials

Related Studies

• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Regulation of Inflammatory Genes in Psoriasis
  Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
• LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
  Enrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
• An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
  Recruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey